Aclarion Secures $4.7 Million in Registered Direct Stock Offering to Advance Healthcare Technology

Aclarion, Inc., a healthcare technology company specializing in innovative diagnostic solutions for chronic low back pain, has initiated a registered direct offering of common stock aimed at advancing its technological capabilities and market presence.

The company plans to sell 506,803 shares at $9.25 per share, with anticipated gross proceeds of approximately $4.7 million. These funds will be strategically allocated to support critical business objectives, including market development, clinical evidence generation, product development, quality enhancement, and general corporate operations.

The offering, facilitated by Dawson James Securities, Inc., is being conducted under a previously filed shelf registration statement that was declared effective by the Securities and Exchange Commission in September 2024. The transaction is expected to close on or around January 31, 2025, contingent upon standard closing conditions.

Aclarion's primary product, Nociscan, represents a significant advancement in medical diagnostics. The platform leverages Magnetic Resonance Spectroscopy, proprietary signal processing techniques, and augmented intelligence algorithms to help physicians precisely identify the source of chronic low back pain. By analyzing chemical biomarkers extracted from MRI data, Nociscan provides critical insights that can potentially optimize treatment strategies.

The company's innovative approach addresses a significant medical challenge, offering healthcare providers a noninvasive method to distinguish between painful and nonpainful spinal discs. This technology could represent a meaningful improvement in diagnostic precision for chronic low back pain, a condition that affects millions of individuals worldwide.

While the offering represents a strategic financial move, Aclarion has acknowledged potential risks and uncertainties associated with the transaction. The company emphasized that forward-looking statements are subject to various market conditions and potential challenges that could impact the anticipated outcomes.

This financial initiative underscores Aclarion's commitment to advancing healthcare technology and developing sophisticated diagnostic tools that could potentially transform pain management and treatment approaches.